Customers in low income countr

1
Comment
Favorite

Customers in low income countries in Asia , Africa could also benefit.

Novo Nordisk to Sell Wegovy at Discount for Cash-Paying US Customers

March 5 - Novo Nordisk said on Wednesday it would offer doses of its weight-loss drug Wegovy at a reduced cost of $499 per month for cash-paying customers in the United States, as it looks to stave off growing competition from compounded versions.Wegovy has a list price of around $1,350 a month, regardless of dosage, not taking any coupons and rebates into account.US-listed shares of Novo Nordisk jumped 4.7% in premarket trading.The move comes just a week after rival Eli Lilly cut the price for

Novo Nordisk to Sell Wegovy at Discount for Cash-Paying US Customers

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment

Top
Latest

No comments yet

Most Discussed

{"i18n":{"language":"en_US"},"data":{"magic":2,"id":410145672962440,"tweetId":"410145672962440","gmtCreate":1741185776226,"gmtModify":1741186180670,"author":{"id":4172323236375242,"idStr":"4172323236375242","authorId":4172323236375242,"authorIdStr":"4172323236375242","name":"InvestToRetire","avatar":"https://community-static.tradeup.com/news/8d70dd9ca2f57b29c925c8b6753b8061","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":12,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":26,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"html":"<html><head></head><body><p>Customers in low income countries in Asia , Africa could also benefit.</p></body></html>","htmlText":"<html><head></head><body><p>Customers in low income countries in Asia , Africa could also benefit.</p></body></html>","text":"Customers in low income countries in Asia , Africa could also benefit.","highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://ttm.financial/post/410145672962440","repostId":2517291118,"repostType":2,"repost":{"id":"2517291118","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"pubTimestamp":1741184136,"share":"https://ttm.financial/m/news/2517291118?lang=en_US&edition=fundamental","pubTime":"2025-03-05 22:15","market":"us","language":"en","title":"Novo Nordisk to Sell Wegovy at Discount for Cash-Paying US Customers","url":"https://stock-news.laohu8.com/highlight/detail?id=2517291118","media":"Reuters","summary":"March 5  - Novo Nordisk said on Wednesday it would offer doses of its weight-loss drug Wegovy at a reduced cost of $499 per month for cash-paying customers in the United States, as it looks to stave off growing competition from compounded versions.Wegovy has a list price of around $1,350 a month, regardless of dosage, not taking any coupons and rebates into account.US-listed shares of Novo Nordisk jumped 4.7% in premarket trading.The move comes just a week after rival Eli Lilly cut the price for","content":"<html><head></head><body><p>March 5 (Reuters) - Novo Nordisk said on Wednesday it would offer doses of its weight-loss drug Wegovy at a reduced cost of $499 per month for cash-paying customers in the United States, as it looks to stave off growing competition from compounded versions.</p><p>Wegovy has a list price of around $1,350 a month, regardless of dosage, not taking any coupons and rebates into account.</p><p>US-listed shares of Novo Nordisk jumped 4.9% in premarket trading.</p><p class=\"t-img-caption\"><img src=\"https://community-static.tradeup.com/news/82dd66b171fe14990d9d5730101ac57b\" tg-width=\"857\" tg-height=\"631\"/></p><p>The move comes just a week after rival Eli Lilly cut the price for vials of its own weight-loss drug Zepbound by $50 or more and expanded the range of doses sold through its LillyDirect website.</p><p>The Wegovy doses, offered through a program called NovoCare Pharmacy, will be available for uninsured patients or eligible patients with commercial insurance who do not have coverage for obesity medicines, the company said.</p><p>The development comes after the U.S. Food and Drug Administration said on February 21 that there was no longer a shortage of Novo Nordisk&#39;s weight-loss and diabetes drugs, Wegovy and Ozempic, a declaration that will curtail widespread sales of cheaper copies made by compounding pharmacies.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novo Nordisk to Sell Wegovy at Discount for Cash-Paying US Customers</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovo Nordisk to Sell Wegovy at Discount for Cash-Paying US Customers\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-03-05 22:15</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>March 5 (Reuters) - Novo Nordisk said on Wednesday it would offer doses of its weight-loss drug Wegovy at a reduced cost of $499 per month for cash-paying customers in the United States, as it looks to stave off growing competition from compounded versions.</p><p>Wegovy has a list price of around $1,350 a month, regardless of dosage, not taking any coupons and rebates into account.</p><p>US-listed shares of Novo Nordisk jumped 4.9% in premarket trading.</p><p class=\"t-img-caption\"><img src=\"https://community-static.tradeup.com/news/82dd66b171fe14990d9d5730101ac57b\" tg-width=\"857\" tg-height=\"631\"/></p><p>The move comes just a week after rival Eli Lilly cut the price for vials of its own weight-loss drug Zepbound by $50 or more and expanded the range of doses sold through its LillyDirect website.</p><p>The Wegovy doses, offered through a program called NovoCare Pharmacy, will be available for uninsured patients or eligible patients with commercial insurance who do not have coverage for obesity medicines, the company said.</p><p>The development comes after the U.S. Food and Drug Administration said on February 21 that there was no longer a shortage of Novo Nordisk&#39;s weight-loss and diabetes drugs, Wegovy and Ozempic, a declaration that will curtail widespread sales of cheaper copies made by compounding pharmacies.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVO":"诺和诺德"},"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250305:nL3N3PO179:1","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2517291118","content_text":"March 5 (Reuters) - Novo Nordisk said on Wednesday it would offer doses of its weight-loss drug Wegovy at a reduced cost of $499 per month for cash-paying customers in the United States, as it looks to stave off growing competition from compounded versions.Wegovy has a list price of around $1,350 a month, regardless of dosage, not taking any coupons and rebates into account.US-listed shares of Novo Nordisk jumped 4.9% in premarket trading.The move comes just a week after rival Eli Lilly cut the price for vials of its own weight-loss drug Zepbound by $50 or more and expanded the range of doses sold through its LillyDirect website.The Wegovy doses, offered through a program called NovoCare Pharmacy, will be available for uninsured patients or eligible patients with commercial insurance who do not have coverage for obesity medicines, the company said.The development comes after the U.S. Food and Drug Administration said on February 21 that there was no longer a shortage of Novo Nordisk's weight-loss and diabetes drugs, Wegovy and Ozempic, a declaration that will curtail widespread sales of cheaper copies made by compounding pharmacies.","news_type":1,"symbols_score_info":{"NVO":1.1}},"isVote":1,"tweetType":1,"viewCount":800,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":59,"optionInvolvedFlag":false,"xxTargetLangEnum":"ORIG"},"commentList":[],"hasMoreComment":false,"orderType":2}